Gilead Beats, Raises, and Falls Anyway on $11.5B of M&A Charges: Upgrading to Outperform

Results vs. Consensus

Quality of Beat/Miss

• Revenue: High quality. The base business grew 8% year over year with double-digit gains in HIV, Trodelvy up 37%, and Livdelzi more than tripling, partly offset by seasonal HCV and cell-therapy softness. The $400M full-year raise is demand-led, not a one-time item.
• Margins: Genuinely improving. Non-GAAP product gross margin stepped to 87% (up 2 points YoY) on the expiration of a long-standing TAF-related royalty plus mix, and operating margin expanded to 47% from 43%. This is structural, not a timing benefit.
• EPS: The $2.03 non-GAAP figure is a clean operating beat (up 12% YoY). The reported full-year loss guidance is entirely a function of the $11.5B upfront IPR&D charge from three deals being expensed in 2026; the ex-transaction EPS run-rate is unchanged. Do not confuse the two.

Segment Performance

HIV — the guide went up, not down

HIV grew 10% year over year to $5.0B, with Biktarvy up 7% to $3.4B (holding U.S. share above 52%) and the U.S. PrEP business up an eye-catching 87%. The sequential declines are Q1 seasonality. The important number is the guide: management raised full-year HIV growth to ~8% from ~6%, inclusive of the same ~2-point policy headwind flagged in February.

"Reflecting this increase to our Yeztugo guidance, in addition to first quarter strength across HIV, we are now expecting 2026 total HIV sales... to grow approximately 8% year-over-year compared to the 6% previously shared in our February guidance." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Raising the HIV growth rate two points one quarter into the year, while absorbing the policy drag, is the clearest evidence the base-business annuity is accelerating rather than maturing. This directly upgrades the most important pillar of the long thesis.

Yeztugo — doubled the guide in one quarter

Yeztugo posted $166M, up 72% sequentially and ahead of plan, with coverage now ~95% (95% at $0 co-pay), leadership in the long-acting switch segment, and growing naive-user initiation. On that outperformance, management raised the 2026 guide to ~$1.0B from the $800M set in February.

"Given the outperformance of Yeztugo in the first quarter and our growing confidence in the trends we're seeing, we're increasing our 2026 Yeztugo guidance to $1 billion, potentially achieving blockbuster status in its first full year." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: In our Q4 note we called $800M a credible floor with upside; management just validated that in one quarter. Early persistency signals are the key remaining unknown, but the direction of travel is unambiguously positive and the guide raise is real, not cosmetic.

Oncology (Trodelvy) — 37% growth into a first-line catalyst

Trodelvy grew 37% year over year and 5% sequentially to $402M, driven by building physician confidence and spontaneous first-line use ahead of formal approval. With NCCN Category 1 recommendations already in place across first-line metastatic TNBC and FDA decisions expected in the second half, Trodelvy is on the cusp of roughly doubling its addressable population.

Assessment: This is the fastest-growing needle-mover in the portfolio and the oncology leg of the diversification thesis is now clearly working. The near-term watch item is competition (Datroway's June PDUFA), but management's read is that first-line expansion plus longer duration of therapy outweighs the entrant.

Liver disease — Livdelzi normalizes after the Q4 switching bolus

Liver sales rose 1% YoY to $767M, with Livdelzi more than tripling year over year to $133M but down 11% sequentially as the Q4 competitor-withdrawal switching bolus normalized. Livdelzi holds more than 50% of the U.S. second-line PBC market, and the Phase 3 IDEAL readout in the second half could expand the label.

Assessment: The sequential dip is exactly what management pre-announced last quarter, so it is not a surprise or a disappointment. The underlying tripling and the market-leadership position keep Livdelzi as a genuine second growth pillar within liver, with IDEAL as free optionality.

Cell therapy (Kite) — still declining, but the offset is now in-house

Kite fell 12% YoY and 11% sequentially to $407M on continued in- and out-of-class competition, tracking the ~10% full-year decline management guided. The strategic change this quarter is that the offset, anito-cel, is now fully owned following the April 28 close of the Arcellx acquisition.

"With the late December PDUFA date and factoring in the time needed for site activation, we expect revenue from anito-cel to begin in early 2027." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Kite remains a 2026 drag, exactly as modeled. But owning anito-cel outright (rather than through a collaboration) reframes cell therapy from managed decline to trough-and-recover, with a December PDUFA and early-2027 revenue start that de-risks the 2027 growth bridge.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Assertive and slightly self-congratulatory, the posture of a team that believes it is playing offense from a position of strength. Management repeatedly framed the three-deal spending spree as optional pipeline-building rather than cliff-driven necessity, and leaned hard on the "ex-transaction EPS is unchanged" message to defuse the reported-loss optics. The one area of visible hedging was Yeztugo persistency, where the honest answer remained that the data is early and imperfect.

1. The $16B, three-deal M&A blitz

The defining event of the quarter was capital allocation, not the P&L. In roughly 60 days Gilead closed Arcellx ($7.8B, anito-cel plus the D-domain binder platform) and struck definitive deals for Tubulis (a next-generation ADC platform with lead ovarian asset TUB-040) and Ouro Medicines (gamgertamig, a BCMAxCD3 T-cell engager for autoimmune disease). Together they deepen oncology, cell therapy, and a nascent inflammation franchise.

"We have one of the strongest portfolios ever in Gilead's history, in fact, the strongest before these acquisitions. And each of these... contribute to different aspects of strengthening our business." — Daniel O'Day, Chairman & CEO

Assessment: This is a meaningful strategic acceleration that trades near-term reported earnings and balance-sheet flexibility for a longer growth runway. Executed from a position of strength (no cliff forcing the hand), it is the right kind of aggression, but it raises the execution bar materially.

2. The reported loss that isn't an operating loss

Because upfront IPR&D must be expensed immediately, the ~$11.5B of deal payments plus financing costs (~$9.50 per share) swing reported 2026 non-GAAP EPS to a $(1.05)–$(0.65) loss and GAAP to $(3.25)–$(2.85). Management was emphatic that the ex-transaction EPS run-rate is unchanged at $8.45–$8.85, and that the $400M revenue raise effectively offsets the incremental operating cost of the deals.

"Excluding these transaction-related costs, we are effectively maintaining our start-of-the-year non-GAAP EPS guidance, highlighting the flexibility in our operating model." — Andrew Dickinson, Chief Financial Officer

Assessment: The market's refusal to look through the charge is precisely the mispricing. A one-time, non-cash accounting treatment of pipeline investment is being read as a fundamental earnings cut. That gap between perception and cash economics is the core of our upgrade.

3. HIV guide raised to ~8%

On the strength of Q1 and the Yeztugo raise, management lifted full-year HIV growth to ~8% from ~6% and base-business growth to 5–6% from 4–5%, all while reaffirming the ~2-point policy headwind. Absent the headwind, base-business growth would be 7–8%.

Assessment: Raising the growth rate this early, into a policy headwind, is the strongest possible signal on demand durability. It moves the HIV pillar from "on track" to accelerating and is the single most thesis-relevant disclosure of the quarter.

4. Yeztugo to $1B and the persistency question

The $800M-to-$1B raise reflects switch leadership, growing naive initiation, ~95% coverage, and a DTC campaign now live. Persistency remains the swing variable; management characterizes early return-user data as encouraging and expects Yeztugo to hold the highest persistency in HIV prevention, but still declines to attach a hard number.

"Still early days... But what we are seeing, we're really pleased with, very encouraging. We do expect Yeztugo's persistency to keep growing over time and to be the highest in the overall HIV prevention market." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: A doubled guide one quarter after launch is a rare and powerful signal. We treat $1B as the new floor. Persistency is the only thing standing between this and a materially larger multi-year number, and every early datapoint so far points the right way.

5. Trodelvy's first-line march and the Datroway threat

Trodelvy's 37% growth reflects spontaneous first-line adoption ahead of second-half FDA decisions, backed by NCCN Category 1 status. The competitive question is AstraZeneca/Daiichi's Datroway (June PDUFA), which claims a survival benefit in immunotherapy-ineligible patients.

Assessment: Management's confidence looks earned given the ASCENT-03/04 data and NCCN positioning, but Datroway is a real second-half watch item. On balance the first-line expansion (roughly doubling the market with longer duration of therapy) outweighs the entrant risk, but it caps how much credit to give the oncology upside today.

6. BIC/LEN (Viclen): the switch-market opening

With an August PDUFA, BIC/LEN targets two pools: the ~5–6% of people with HIV still on complex multi-pill regimens, and the ~20% "switch" market where patients rotate to the newest option. Critically, it lets Gilead retain patients who would otherwise switch off Biktarvy to a competitor.

"We believe with BIC/LEN, there's an opportunity to play in that switch market, which we haven't had in the past and moved them from Biktarvy, if they're going to switch anyway, to BIC/LEN." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: This is a smart defensive-plus-offensive play that plugs the one leak in the Biktarvy franchise. Modest in 2026 on a late-August launch, but a durable share-retention tool that extends the HIV annuity well beyond Biktarvy's 2036 LOE.

7. Anito-cel and the cell-therapy turn

With Arcellx closed, anito-cel is fully owned, iMMagine-3 (2L–4L) is enrolling ahead of plan, and management is designing newly-diagnosed studies. A December PDUFA points to an early-2027 launch, with a majority of authorized treatment centers expected active by Q1 2027.

Assessment: Anito-cel converts Kite from a drag narrative into a 2027 growth story. The differentiated safety profile matters more as the therapy moves to earlier lines, and full ownership means Gilead captures the full economics rather than sharing them.

8. Margin discipline while integrating three deals

Operating margin expanded to 47% from 43% even as the company absorbs three integrations plus four launches, with roughly $400M of incremental 2026 expense offset by revenue outperformance. Management guided to further margin room in 2027 and beyond as late-stage trials wind down.

"You see our ability with the revenue outperformance and the disciplined expense management to pull those in and offset that... there is room to strengthen the margin over time." — Andrew Dickinson, Chief Financial Officer

Assessment: The ability to swallow three deals without denting the operating-margin trajectory is exactly the earnings-quality signature that supports a premium multiple. It also underwrites the ex-transaction EPS guide the market is currently ignoring.

9. Policy headwind reaffirmed, not worsened

The ~2-point 2026 growth headwind from the Medicaid pricing agreement and ACA changes was reaffirmed, not escalated, and is fully baked into the raised guide.

Assessment: Stability here is a positive. The bear worry is the multi-year path of U.S. drug pricing, which remains unsized, but the fact that management raised guidance through the headwind shows the base business can grow past it in 2026.

10. Capital-allocation reset: integrate, don't acquire

After the spending spree, management signaled the near-term BD focus shifts to closing and integrating the three deals, with sizable further M&A now less likely this year.

"It is less likely that we will pursue more sizable M&A this year, although we will always leave the door open to consider strategic acquisitions if a compelling opportunity emerges." — Andrew Dickinson, Chief Financial Officer

Assessment: A sensible pause. It lowers the risk of over-extension and lets the market refocus on execution and the ex-transaction earnings power, which is where we think the re-rating comes from once the charge is in the rear-view mirror.

Guidance & Outlook

The guide is a tale of two income statements. The operating story got better across the board: product sales, base business, HIV growth, Yeztugo, and ex-transaction operating income all moved up. The reported story got dramatically worse on paper, swinging to a loss purely because ~$11.5B of upfront deal payments must be expensed in 2026. The raised product-sales range of $30.0–$30.4B sits roughly in line with the ~$30.8B Street sales estimate, so management is guiding the rest of the year to broadly meet expectations while flagging upside optionality from launches.

Implied ramp: The 5–6% base-business guide leans on HIV (~8%), Trodelvy's first-line launch, and Livdelzi, offset by a ~10% Kite decline and the Veklury step-down. Yeztugo's doubled ~$1.0B contribution is now roughly the single largest incremental growth driver in the base business.

Guidance style: Consistent with Gilead's guide-to-a-floor pattern. Raising revenue and HIV growth one quarter in, and doubling Yeztugo, both point to conservative initial framing, the same setup we flagged in the Q4 note.

Analyst Q&A Highlights

Where the value sits in the Tubulis deal

The first question probed how much of the Tubulis valuation rests on ovarian cancer versus a potential lung expansion for TUB-040, and what validation the PD-1/VEGF class would need before Gilead pursues ADC combinations. Management framed the ovarian opportunity as sufficient on its own to justify the price.

Q: "How much of that NPV was driven by ovarian and the signal you're seeing there for 040 versus the potential to take this into lung given the amount of NaPi2b expression there?"
— Akash Tewari, Jefferies

A: "The ovarian opportunity alone is very large. The data is really encouraging. The financial return... on ovarian cancer alone [would] justify the transaction price. You're absolutely right, there is upside in lung cancer potentially."
— Andrew Dickinson, Chief Financial Officer

Assessment: Underwriting a deal on the lead indication alone, with lung as free optionality, is disciplined framing. It suggests the ADC platform is being bought at a price defensible on near-term visibility rather than blue-sky assumptions.

Absorbing three integrations without breaking margins

A direct question on near- and long-term margins given three simultaneous integrations plus multiple launches drew a confident answer: the revenue beat offsets the incremental spend this year, and management sees margin room in 2027 and beyond.

Q: "You guys have had 3 new acquisition integrations running simultaneously alongside multiple commercial launches. How should we think about margins in the near term and the long term? Is there room for continued margin expansion, particularly in that '27 to '28 time frame?"
— Alex Hammond, Wolfe Research

A: "You see in the first quarter a 47% operating margin, significant strengthening... our ability with the revenue outperformance and the disciplined expense management to pull those in and offset that... '28 and beyond... you should still expect very strong financial performance on the bottom line and the top line, and there is room to strengthen the margin over time."
— Andrew Dickinson, Chief Financial Officer

Assessment: The margin answer is the crux of the bull case: the deals are being absorbed without denting operating leverage. If management delivers on this, the ex-transaction earnings power the market is ignoring becomes visible again in 2027.

Yeztugo switch/naive mix and the $1B adherence assumption

A recurring line of questioning pressed on the composition of Yeztugo demand and what adherence assumption underpins the doubled guide. Management gave unusual granularity on switch mix but held back on a precise persistency figure.

Q: "Can you provide the latest mix of switch versus naive? And then anything new on the adherence assumption that's embedded in the $1 billion guidance?"
— Terence Flynn, Morgan Stanley

A: "Switch share is obviously greater than the naive, but naive is coming along really quite nicely... In the switch share, we see a bit of a split across [roughly] a third, a third, a third across [other long-acting injectables], the Truvada generics, as well as Descovy... Still early days [on persistency]... very encouraging."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: The switch/naive detail is encouraging (naive uptake is the harder, higher-value cohort). The persistency non-answer remains the one soft spot, but every qualitative signal points to the raised guide being conservative.

Trodelvy versus a new first-line competitor

Questioning turned to whether AstraZeneca/Daiichi's Datroway, with a June PDUFA and a claimed survival benefit, changes Trodelvy's TNBC opportunity. Management leaned on the 37% growth and NCCN Category 1 positioning.

Q: "How you're thinking about the impact to Trodelvy sales in triple negative... in the case that AstraZeneca and Daiichi's Datroway is approved... they're claiming a superior overall survival benefit... Does that change what you think the market opportunity is?"
— Tazeen Ahmad, Bank of America

A: "A lot of that growth is really driven by the confidence that is building with physicians with Trodelvy... What we've seen since the publications and the NCCN guidelines updating us to a Category 1 for both first-line PD-L1 negative as well as PD-L1 positive... is a really nice uptake in earlier lines."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Management sidestepped a direct Datroway comparison and pivoted to Trodelvy's entrenchment and guideline status. Reasonable, but it leaves the competitive dynamic as a genuine second-half watch item rather than a settled question.

BIC/LEN and the size of the switch opportunity

A question on the attractiveness of BIC/LEN ahead of its August launch drew a two-part framing: the complex-regimen simplification pool and the broader switch market, including patients who would otherwise leave Biktarvy.

Q: "5% to 6% of the HIV market could still be a sizable opportunity. Could you please help us understand the opportunity here? And how big this product could be even in the switch market?"
— Mohit Bansal, Wells Fargo

A: "There's still about 5% to 6% [of] people living with HIV that are on multiple pills... an opportunity to simplify... In addition... in the switch market... there's about 20% or so of that switch... With BIC/LEN, there's an opportunity to play in that switch market, which we haven't had in the past."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: BIC/LEN is a franchise-defense asset as much as a growth one. Plugging the switch-off leak from Biktarvy is strategically valuable and extends HIV durability past Biktarvy's own LOE.

Anito-cel safety as the therapy moves upstream

An exchange explored whether anito-cel's safety advantage among CAR-Ts widens or narrows in earlier, less heavily pretreated lines. Management argued the advantage matters more upstream.

Q: "As you approach the launch and looking at the development in earlier lines... would we expect [the safety advantage] to narrow or to widen as you treat patients upstream that are maybe less heavily pretreated?"
— Geoff Meacham, Citi

A: "We actually agree with the statement you just made. We're really excited about the potential for anito-cel going into earlier lines... So safety really matters at that point... coupled with the safety profile, we think it's going to be a really important option for patients in earlier lines."
— Cindy Perettie, EVP, Kite

Assessment: The earlier-line thesis is where anito-cel's economics get interesting, and a widening safety edge upstream is the argument for a much larger long-term market than the $3.5B fourth-line-plus base. It underpins the 2027-and-beyond cell-therapy recovery.

What They're NOT Saying

1. A hard Yeztugo persistency number: Management again declined to quantify second-dose refill rates, conceding the claims data "is not perfect." Persistency compounds a twice-yearly drug's base, so it remains the single largest unquantified driver of the 2027+ trajectory.
2. The oral alpha-4 beta-7 UC readout: Asked directly why there was no update on a Phase 2 ulcerative colitis trial that appears to have completed, management said only to "not read anything into the timeline." A completed trial without disclosed data is worth watching.
3. Weekly oral capsid+INSTI molecule selection: The wholly-owned weekly oral treatment combination is still finalizing its component molecules, leaving a piece of the "seven launches by 2033" HIV roadmap undefined.
4. Peak-sales frames: No explicit peak-sales guidance for Trodelvy first-line, anito-cel, or Yeztugo. Management is guiding trajectory, not destination, which leaves the biggest upside cases loosely sized.
5. Balance-sheet detail on the deal wave: Cash and marketable securities fell to $8.6B from $10.6B, but management gave limited color on financing structure for ~$16B of deals beyond noting associated financing costs, leaving leverage and buyback capacity for 2026–27 somewhat open.

Market Reaction

• Pre-print setup: GILD closed at $134.06 entering the print, down roughly 14% from the Q4 record close of $155.80 and down 3.4% over the trailing 30 days, but still up 9.2% YTD and 35.6% over the trailing twelve months. The stock had already given back a chunk of its early-2026 run.
• After-hours / reaction move: Despite the beat and the revenue raise, shares gapped down about 3.0% and closed the May 8 session at $131.33, down 2.0% (a $2.73 move) on 1.9x average volume. The S&P 500 rose 0.8% that day, so GILD underperformed the tape by roughly three points.

The decline was an accounting reaction, not an operating one. The market keyed on the headline swing to a reported full-year loss and on integration risk (three deals plus four launches), rather than on the clean base-business beat, the raised revenue and HIV guides, and the doubled Yeztugo number. That is precisely the kind of dislocation we want to buy: a de-rated stock, a rising estimate, and a sell-off driven by a non-cash charge the market is unwilling to look through. The post-print Street median target near $160 implies meaningful upside from the reaction close.

Street Perspective

Debate: Should investors look through the $11.5B IPR&D charge?

Bull view: The charge is a one-time, non-cash accounting treatment of pipeline investment; ex-transaction EPS is unchanged at $8.45–$8.85, and 2027 normalizes, so the reported loss is noise.

Bear view: The cash actually went out the door (~$16B), balance-sheet flexibility shrank, and "look through the charge" is what every acquirer says right before integration disappoints.

Our take: The bull is right on the economics. This is pipeline capex expensed at once, not earnings erosion, and the market's refusal to look through it is the mispricing we are upgrading into.

Debate: Smart pipeline-building or overreach?

Bull view: Three high-quality platforms (CAR-T, ADC, T-cell engager) bought from a position of strength deepen the post-2027 growth runway and diversify beyond HIV, exactly what a durable compounder should do while it can.

Bear view: Spending $16B in 60 days across three integrations, alongside four launches, is a lot of simultaneous execution risk for assets whose first meaningful revenue is 2027 at the earliest.

Our take: The execution bar is genuinely higher now, and we respect the bear point. But the assets are strategically coherent and the near-term drag is non-cash, so the risk/reward favors the buyer that gets paid to wait via a de-rated multiple and a ~2.4% yield.

Debate: Is the de-rated valuation plus raised guide a buy here?

Bull view: At ~15x ex-transaction 2026 EPS with a rising estimate, an accelerating base business, and Yeztugo/Trodelvy/anito-cel catalysts stacking into 2026–27, the setup is the most attractive it has been in a year.

Bear view: Reported numbers are ugly through 2026, the policy overhang persists, and the market may not re-rate the stock until the charge is behind it and 2027 estimates are in hand.

Our take: We side with the bulls but acknowledge the re-rating may be a two-to-three-quarter story rather than an immediate one. The entry is good enough that we are willing to wait.

Model Update Needed

Valuation impact: At the $131.33 reaction close, GILD trades at roughly 15x the ex-transaction 2026 EPS midpoint of ~$8.65 (a P/E that would look messy on reported EPS but is the right lens given the one-time charge). That is a discount to where the stock traded post-Q4 (~18x) despite a higher revenue outlook and an accelerating base business. Against a post-print Street median target near $160, the implied upside is roughly 20%-plus. We see fair value in the high-$150s to low-$160s once the charge rolls off and 2027 estimates come into view, comfortably enough to support an Outperform.

Thesis Scorecard Post-Earnings

Overall: Thesis strengthened. Every operating pillar improved, the valuation constraint that kept us at Hold has resolved via the pullback, and the market handed us a non-cash-charge-driven dislocation. The one genuinely new risk is integration execution across three deals.

Action: Upgrade to Outperform. The de-rated valuation, the raised guide, Yeztugo's outperformance, and Trodelvy's inflection outweigh the integration risk and the policy overhang. Buy the accounting-driven dislocation; the re-rating should follow as the charge rolls off and 2027 estimates come into view.